ScanScor NDAPR Events
Total Events
705
Alerts
241
Active
513
Partial / Realized
140 / 6
Broken / Expired
44 / 0
YES_UP / YES_DOWN / NONE
205 / 37 / 463
| Created | Ticker | Status | Direction | Window / Target | Catalyst | Reason / Rationale |
|---|---|---|---|---|---|---|
|
2026-06-25 20:02:17
Event ID 783
Report 1615
|
NRXP
NO_CHANGE
|
ACTIVE
ALERT
Parse: PARSED
|
YES_DOWN
Breakout:
DBR: {"expected_direction":"PARTIAL_DELAY","directional_odds_up_down":"45_55","downside_risk":"HIGH","potential_high":"4.80","potential_low":"1.70","dbr_action":"REVISE"}
|
Primary FDA ketamine catalyst still pending; dispute news is non-core but adds execution noise. Catalyst progress. Kadima litigation and acquisition dispute add distraction and execution risk, but do not change the summer 2026 FDA ketamine decision window. |
||
|
2026-06-25 11:12:56
Event ID 782
Report 1656
|
AUTL
NO_CHANGE
|
ACTIVE
Parse: PARSED
|
NONE
Breakout:
DBR: {"expected_direction":"PARTIAL_DELAY","directional_odds_up_down":"55_45","downside_risk":"HIGH","potential_high":"2.60","potential_low":"1.25","dbr_action":"UNCHANGED"}
|
Primary Q2 commercial update catalyst still pending Investor conference participation is non-value-bearing scheduling news only; Catalyst progress. the August Q2 commercial update remains the thesis-defining event. |
||
|
2026-06-25 11:02:51
Event ID 781
Report 1660
|
AVIR
NO_CHANGE
|
ACTIVE
ALERT
Parse: PARSED
|
YES_UP
Breakout:
DBR: {"expected_direction":"UP","directional_odds_up_down":"64_36","downside_risk":"HIGH","potential_high":"8.50","potential_low":"2.80","dbr_action":"REAFFIRM"}
|
Primary C-BEYOND topline catalyst still pending; C-FORWARD enrollment completion is supportive progress only. Catalyst progress. C-FORWARD enrollment completion supports execution and broad-label potential, while C-BEYOND mid-year topline remains the unresolved price-setting event. |
||
|
2026-06-25 11:02:45
Event ID 780
Report 1615
|
NRXP
REVISE
|
ACTIVE
Parse: PARSED
|
NONE
Breakout: 37
DBR: {"expected_direction":"PARTIAL_DELAY","directional_odds_up_down":"55_45","downside_risk":"HIGH","potential_high":"4.60","potential_low":"1.80","dbr_action":"REVISE"}
|
2026-06-25 to 2026-08-07 Target: $4.60 |
Summer 2026 FDA ketamine decision remains primary catalyst, with commercial HOPE clinic rollout progress offset by financing and litigation overhang. |
Primary FDA catalyst still pending Catalyst progress. First Zeta-guided treatments support commercial buildout, but recent dilution and acquisition litigation modestly weaken odds of hitting the FDA-driven target. |
|
2026-06-25 10:27:13
Event ID 779
Report 1645
|
PRQR
REVISE
|
BROKEN
ALERT
Parse: PARSED
|
YES_UP
Breakout: 52
DBR: {"expected_direction":"UP","directional_odds_up_down":"68_32","downside_risk":"HIGH","potential_high":"3.60","potential_low":"1.20","dbr_action":"REVISE"}
|
2026-06-25 to 2027-06-30 Target: $3.60 |
Post-target-engagement follow-through via full Phase 1 data, AX-0811 CTA, and biliary atresia development updates |
News indicated primary catalyst was delayed more than 30 days Catalyst hit. Positive AX-0810 human target-engagement and safety data validate Axiomer, shifting the thesis to follow-through execution and franchise expansion. |
|
2026-06-24 17:23:44
Event ID 778
Report 1615
|
NRXP
REVISE
|
ACTIVE
ALERT
Parse: PARSED
|
YES_DOWN
Breakout: 31
DBR: {"expected_direction":"DOWN","directional_odds_up_down":"35_65","downside_risk":"HIGH","potential_high":"4.20","potential_low":"1.60","dbr_action":"REVISE"}
|
2026-06-24 to 2026-08-07 Target: $4.20 |
Summer 2026 FDA ketamine approval path remains primary, but litigation and financing credibility overhang may cap upside. |
Primary FDA catalyst still pending despite new litigation overhang Catalyst progress. Lawsuit alleging misrepresentation and funding weakness raises governance risk and likely weakens odds of reaching the prior target before FDA review. |
|
2026-06-23 22:36:35
Event ID 777
Report 1585
|
VSTM
REVISE
|
PARTIALLY_REALIZED
ALERT
Parse: PARSED
|
YES_UP
Breakout: 45
DBR: {"expected_direction":"UP","directional_odds_up_down":"65_35","downside_risk":"HIGH","potential_high":"10.50","potential_low":"3.50","dbr_action":"REVISE"}
|
2026-06-23 to 2026-09-30 Target: $10.50 |
VS-7375 follow-up clinical updates and early registration-directed trial progress |
Initial VS-7375 clinical activity reported, but fuller efficacy validation remains pending Catalyst hit. Positive early VS-7375 activity supports the thesis, but preliminary Phase 1/2 data and remaining follow-up reduce near-window certainty. |
|
2026-06-23 18:02:13
Event ID 776
Report 1577
|
CHRS
NO_CHANGE
|
ACTIVE
ALERT
Parse: PARSED
|
YES_UP
Breakout:
DBR: {"expected_direction":"UP","directional_odds_up_down":"60_40","downside_risk":"HIGH","potential_high":"2.50","potential_low":"1.10","dbr_action":"REAFFIRM"}
|
Main first-half 2026 data readouts still pending Catalyst progress. New LOQTORZI combination collaboration supports pipeline breadth, but it does not deliver the predicted CHS-114 or Casdozokitug readouts. |
||
|
2026-06-23 15:05:57
Event ID 775
Report 1615
|
NRXP
NO_CHANGE
|
ACTIVE
Parse: PARSED
|
NONE
Breakout:
DBR: {"expected_direction":"PARTIAL_DELAY","directional_odds_up_down":"55_45","downside_risk":"HIGH","potential_high":"4.80","potential_low":"1.60","dbr_action":"REAFFIRM"}
|
Primary FDA ketamine catalyst still pending Catalyst progress. HOPE’s first Zeta-guided TMS treatment supports commercial build-out, but it does not alter the summer 2026 FDA ketamine decision thesis. |
||
|
2026-06-23 13:52:55
Event ID 774
Report 1625
|
IGC
REVISE
|
BROKEN
Parse: PARSED
|
NONE
Breakout: 46
DBR: {"expected_direction":"PARTIAL_DELAY","directional_odds_up_down":"55_45","downside_risk":"HIGH","potential_high":"0.42","potential_low":"0.22","dbr_action":"REVISE"}
|
2026-06-23 to 2026-08-15 Target: $0.42 |
CALMA enrollment target has been reached; next meaningful catalyst is completion of over-enrollment, follow-up, database activities, and subsequent topline Phase 2 analysis. |
News indicated primary catalyst was delayed more than 30 days Catalyst hit. The enrollment target was reached, while today’s AI update is secondary and Catalyst progress shifts focus beyond the prior July window. |
|
2026-06-22 20:44:36
Event ID 773
Report 1638
|
MGNX
NO_CHANGE
|
ACTIVE
ALERT
Parse: PARSED
|
YES_UP
Breakout:
DBR: {"expected_direction":"UP","directional_odds_up_down":"60_40","downside_risk":"HIGH","potential_high":"5.25","potential_low":"2.20","dbr_action":"REAFFIRM"}
|
Non-dilutive cash support, primary mid-2026 clinical catalyst still pending Catalyst progress. Sanofi milestone adds non-dilutive cash and modestly supports execution, but the LINNET/MGC026 thesis-defining clinical update has not occurred. |
||
|
2026-06-22 13:17:04
Event ID 772
Report 1630
|
CELZ
REVISE
|
BROKEN
ALERT
Parse: PARSED
|
YES_UP
Breakout: 46
DBR: {"expected_direction":"PARTIAL_DELAY","directional_odds_up_down":"60_40","downside_risk":"HIGH","potential_high":"3.85","potential_low":"1.65","dbr_action":"REVISE"}
|
2026-06-22 to 2026-09-30 Target: $3.85 |
Expanded ADAPT cohort completion, additional ADAPT data, and FDA Phase 3 planning discussions for olastrocel |
News indicated primary catalyst was delayed more than 30 days Catalyst progress. FDA-cleared ADAPT expansion extends the timeline but strengthens clinical and regulatory momentum toward later-stage development. |
|
2026-06-22 12:32:19
Event ID 771
Report 1661
|
ACHV
REVISE
|
BROKEN
ALERT
Parse: PARSED
|
YES_DOWN
Breakout: 18
DBR: {"expected_direction":"DOWN","directional_odds_up_down":"20_80","downside_risk":"HIGH","potential_high":"3.50","potential_low":"2.25","dbr_action":"REVISE"}
|
2026-06-22 to 2027-06-30 Target: $3.50 |
CRL received; next meaningful catalyst is NDA resubmission in Q4 2026 and potential FDA approval in 1H 2027. |
News indicated primary catalyst was delayed more than 30 days Catalyst hit. FDA issued a CRL, breaking the approval thesis; Catalyst progress remains via Adare transfer and planned Q4 resubmission. |
|
2026-06-22 12:32:10
Event ID 770
Report 1605
|
ENTX
REVISE
|
REALIZED
ALERT
Parse: PARSED
|
YES_UP
Breakout: 75
DBR: {"expected_direction":"UP","directional_odds_up_down":"75_25","downside_risk":"HIGH","potential_high":"3.75","potential_low":"0.95","dbr_action":"REVISE"}
|
2026-06-22 to 2026-12-31 Target: $3.75 |
Positive FDA feedback received; focus shifts to Phase 3 initiation and financing execution for EB613. |
Positive FDA feedback on the streamlined registrational Phase 3 plan was received. Catalyst hit. Positive FDA feedback validates EB613’s streamlined registrational path, though financing and late-2026 Phase 3 initiation still cap upside. |
|
2026-06-22 11:02:03
Event ID 769
Report 1615
|
NRXP
NO_CHANGE
|
ACTIVE
ALERT
Parse: PARSED
|
YES_UP
Breakout:
DBR: {"expected_direction":"UP","directional_odds_up_down":"58_42","downside_risk":"HIGH","potential_high":"4.80","potential_low":"1.80","dbr_action":"REAFFIRM"}
|
Primary ketamine FDA catalyst still pending Catalyst progress. Expanded access for NRX-101 is supportive, but the main summer 2026 ketamine FDA approval catalyst has not occurred. |
||
|
2026-06-18 20:10:43
Event ID 768
Report 1663
|
ACET
NO_CHANGE
|
ACTIVE
Parse: PARSED
|
NONE
Breakout:
DBR: {"expected_direction":"UNCERTAIN","directional_odds_up_down":"55_45","downside_risk":"HIGH","potential_high":"15.50","potential_low":"6.50","dbr_action":"UNCHANGED"}
|
8-K appears shareholder-vote/boilerplate, primary clinical and FDA catalysts still pending Catalyst progress. The 8-K does not show the mid-2026 data or pivotal-path outcome, so the thesis window and target remain unchanged. |
||
|
2026-06-18 15:50:09
Event ID 767
Report 1572
|
PRTA
REVISE
|
ACTIVE
ALERT
Parse: PARSED
|
YES_UP
Breakout: 68
DBR: {"expected_direction":"UP","directional_odds_up_down":"68_32","downside_risk":"HIGH","potential_high":"13.50","potential_low":"6.50","dbr_action":"REVISE"}
|
2026-06-18 to 2026-08-31 Target: $13.50 |
PRX012 Phase I/II Alzheimer's data expected in mid-2026, supported by repeated insider buying |
Primary PRX012 data catalyst remains pending within current window Catalyst progress. Repeated insider purchases modestly strengthen confidence, but the PRX012 data catalyst has not yet occurred. |
|
2026-06-18 12:01:27
Event ID 766
Report 1623
|
ALLR
NO_CHANGE
|
ACTIVE
Parse: PARSED
|
NONE
Breakout:
DBR: {"expected_direction":"PARTIAL_DELAY","directional_odds_up_down":"55_45","downside_risk":"HIGH","potential_high":"2.40","potential_low":"0.95","dbr_action":"REAFFIRM"}
|
Enrollment-completion catalyst still pending Catalyst progress. Trial-in-progress poster raises visibility but provides no new clinical data or enrollment-completion update, leaving the original ovarian enrollment catalyst unchanged. |
||
|
2026-06-17 20:10:28
Event ID 765
Report 1595
|
BFRI
REVISE
|
ACTIVE
ALERT
Parse: PARSED
|
YES_DOWN
Breakout: 62
DBR: {"expected_direction":"DOWN","directional_odds_up_down":"40_60","downside_risk":"HIGH","potential_high":"1.35","potential_low":"0.60","dbr_action":"REVISE"}
|
2026-08-30 to 2026-10-15 Target: $1.35 |
September 2026 PDUFA for sBCC with added financing overhang |
Primary PDUFA catalyst still pending; financing raises dilution risk Catalyst progress. Financing-related 8-K suggests dilution/runway pressure, weakening odds of hitting the pre-PDUFA upside target before October. |
|
2026-06-17 20:02:29
Event ID 764
Report 1659
|
LXEO
REVISE
|
PARTIALLY_REALIZED
ALERT
Parse: PARSED
|
YES_UP
Breakout: 44
DBR: {"expected_direction":"UP","directional_odds_up_down":"65_35","downside_risk":"MEDIUM","potential_high":"8.50","potential_low":"3.80","dbr_action":"REVISE"}
|
2026-06-17 to 2026-06-30 Target: $8.50 |
SUNRISE-FA 2 pivotal trial initiation and first-patient enrollment by end of June |
Supportive publication and protocol finalization de-risked thesis, but pivotal trial initiation remains pending Catalyst progress: JAMA publication and June guidance strengthen confidence, but the main stock-moving catalyst is still SUNRISE-FA 2 initiation. |
|
2026-06-17 16:38:14
Event ID 763
Report 1607
|
SPRO
REVISE
|
REALIZED
ALERT
Parse: PARSED
|
YES_UP
Breakout: 85
DBR: {"expected_direction":"UP","directional_odds_up_down":"80_20","downside_risk":"MEDIUM","potential_high":"4.50","potential_low":"2.20","dbr_action":"REVISE"}
|
2026-06-10 to 2026-06-17 Target: $4.50 |
FDA approval of Utebzi for cUTI |
FDA approval granted for the primary predicted catalyst Catalyst hit. FDA approval materially fulfills the thesis and strengthens upside re-rating potential despite launch timing extending to late 2026. |
|
2026-06-17 13:02:17
Event ID 762
Report 1612
|
CNTB
REVISE
|
BROKEN
ALERT
Parse: PARSED
|
YES_UP
Breakout: 56
DBR: {"expected_direction":"PARTIAL_DELAY","directional_odds_up_down":"60_40","downside_risk":"HIGH","potential_high":"5.50","potential_low":"1.60","dbr_action":"REVISE"}
|
2026-06-17 to 2026-09-30 Target: $5.50 |
Topline data from Seabreeze STAT asthma in early September 2026, followed soon after by COPD topline and potential FDA Phase 3 alignment. |
News indicated primary catalyst was delayed more than 30 days Catalyst progress: asthma enrollment completed, but topline moved to early September, pushing the key readout beyond the prior July window. |
|
2026-06-17 13:00:09
Event ID 761
Report 1585
|
VSTM
NO_CHANGE
|
PARTIALLY_REALIZED
ALERT
Parse: PARSED
|
YES_UP
Breakout:
DBR: {"expected_direction":"UP","directional_odds_up_down":"65_35","downside_risk":"HIGH","potential_high":"16.57","potential_low":"3.50","dbr_action":"REAFFIRM"}
|
Supportive clinical progress, but VS-7375 updated data catalyst not yet disclosed Catalyst progress. Positive RAMP 205 data supports pipeline sentiment, but the original VS-7375 mid-2026 data catalyst remains pending within the current window. |
||
|
2026-06-17 12:41:53
Event ID 760
Report 1585
|
VSTM
REVISE
|
PARTIALLY_REALIZED
ALERT
Parse: PARSED
|
YES_UP
Breakout: 55
DBR: {"expected_direction":"UP","directional_odds_up_down":"65_35","downside_risk":"HIGH","potential_high":"12.00","potential_low":"3.50","dbr_action":"REVISE"}
|
2026-06-17 to 2026-09-30 Target: $12.00 |
VS-7375 program progress and additional pancreatic cancer data updates |
Supportive pancreatic data arrived, but original VS-7375 thesis-defining update remains incomplete Catalyst progress. Positive RAMP 205 data and VS-7375 trial initiation support upside, but the original VS-7375 data catalyst is not fully hit. |
|
2026-06-16 22:24:09
Event ID 759
Report 1585
|
VSTM
NO_CHANGE
|
ACTIVE
Parse: PARSED
|
NONE
Breakout:
DBR: {"expected_direction":"UP","directional_odds_up_down":"65_35","downside_risk":"HIGH","potential_high":"16.57","potential_low":"3.50","dbr_action":"UNCHANGED"}
|
Primary mid-2026 VS-7375 data catalyst still pending Catalyst progress. Conference presentation news does not deliver the thesis-defining VS-7375 data or alter the current mid-2026 catalyst window. |
||
|
2026-06-16 22:20:42
Event ID 758
Report 1585
|
VSTM
NO_CHANGE
|
PARTIALLY_REALIZED
ALERT
Parse: PARSED
|
YES_UP
Breakout:
DBR: {"expected_direction":"UP","directional_odds_up_down":"65_35","downside_risk":"HIGH","potential_high":"16.57","potential_low":"3.50","dbr_action":"REAFFIRM"}
|
Fast Track supports VS-7375 development, but mid-2026 updated clinical data remains the main pending catalyst Catalyst progress. Fast Track strengthens VS-7375 credibility and timeline support, but the thesis-defining updated clinical data has not yet been released. |
||
|
2026-06-16 22:20:23
Event ID 757
Report 1585
|
VSTM
NO_CHANGE
|
PARTIALLY_REALIZED
Parse: PARSED
|
NONE
Breakout:
DBR: {"expected_direction":"PARTIAL_DELAY","directional_odds_up_down":"60_40","downside_risk":"HIGH","potential_high":"16.57","potential_low":"3.50","dbr_action":"REAFFIRM"}
|
VS-7375 program advanced, but mid-2026 updated data catalyst remains pending Catalyst progress: earnings-date news is non-material to the mid-2026 VS-7375 data thesis, which remains pending despite broader pipeline advancement. |
||
|
2026-06-16 22:20:01
Event ID 756
Report 1585
|
VSTM
NO_CHANGE
|
ACTIVE
Parse: PARSED
|
NONE
Breakout:
DBR: {"expected_direction":"PARTIAL_DELAY","directional_odds_up_down":"60_40","downside_risk":"HIGH","potential_high":"16.57","potential_low":"3.50","dbr_action":"REAFFIRM"}
|
Conference abstract signals upcoming VS-7375 data but catalyst outcome not yet disclosed Catalyst progress. Late-breaking abstract supports mid-2026 VS-7375 data timing without changing the existing August 2026 catalyst window. |
||
|
2026-06-16 22:19:42
Event ID 755
Report 1585
|
VSTM
NO_CHANGE
|
ACTIVE
Parse: PARSED
|
NONE
Breakout:
DBR: {"expected_direction":"UP","directional_odds_up_down":"65_35","downside_risk":"HIGH","potential_high":"16.57","potential_low":"3.50","dbr_action":"UNCHANGED"}
|
Investor conference announcement only; VS-7375 data catalyst still pending Catalyst progress. Conference participation does not deliver the mid-2026 VS-7375 data catalyst or materially alter target timing, probability, or price objective. |
||
|
2026-06-16 22:18:58
Event ID 754
Report 1585
|
VSTM
REVISE
|
PARTIALLY_REALIZED
ALERT
Parse: PARSED
|
YES_UP
Breakout: 72
DBR: {"expected_direction":"UP","directional_odds_up_down":"72_28","downside_risk":"HIGH","potential_high":"16.57","potential_low":"3.80","dbr_action":"REVISE"}
|
2026-06-15 to 2026-08-31 Target: $16.57 |
Updated VS-7375 TARGET-D clinical data and program progress in mid-2026 |
Preliminary VS-7375 data released, but broader mid-2026 update thesis is not fully resolved Catalyst progress. Encouraging preliminary VS-7375 data and expanding registration-directed development strengthen upside odds within the existing mid-2026 catalyst window. |
|
2026-06-16 22:18:32
Event ID 753
Report 1585
|
VSTM
NO_CHANGE
|
ACTIVE
Parse: PARSED
|
NONE
Breakout:
DBR: {"expected_direction":"UNCERTAIN","directional_odds_up_down":"50_50","downside_risk":"HIGH","potential_high":"16.57","potential_low":"3.50","dbr_action":"UNCHANGED"}
|
Main mid-2026 VS-7375 data catalyst still pending Catalyst progress. Investor conference participation adds no thesis-defining data and does not alter the mid-2026 VS-7375 catalyst window. |
||
|
2026-06-16 22:18:14
Event ID 752
Report 1585
|
VSTM
NO_CHANGE
|
PARTIALLY_REALIZED
ALERT
Parse: PARSED
|
YES_DOWN
Breakout:
DBR: {"expected_direction":"DOWN","directional_odds_up_down":"35_65","downside_risk":"HIGH","potential_high":"16.57","potential_low":"4.50","dbr_action":"REVISE"}
|
VS-7375 program advanced, but target data catalyst not yet delivered Catalyst progress, but a proposed equity offering is dilutive and likely pressures shares despite the mid-2026 VS-7375 data thesis remaining intact. |
||
|
2026-06-16 22:17:59
Event ID 751
Report 1585
|
VSTM
NO_CHANGE
|
ACTIVE
ALERT
Parse: PARSED
|
YES_DOWN
Breakout:
DBR: {"expected_direction":"PARTIAL_DELAY","directional_odds_up_down":"55_45","downside_risk":"HIGH","potential_high":"16.57","potential_low":"4.50","dbr_action":"REAFFIRM"}
|
Primary mid-2026 VS-7375 data catalyst still pending Catalyst progress; dilutive financing is near-term negative, but the mid-2026 VS-7375 data catalyst has not occurred. |
||
|
2026-06-16 22:17:31
Event ID 750
Report 1585
|
VSTM
NO_CHANGE
|
ACTIVE
Parse: PARSED
|
NONE
Breakout:
DBR: {"expected_direction":"UP","directional_odds_up_down":"65_35","downside_risk":"HIGH","potential_high":"16.57","potential_low":"3.50","dbr_action":"UNCHANGED"}
|
Primary VS-7375 mid-2026 data catalyst still pending Inducement grants are non-catalytic compensation news; Catalyst progress. they do not alter the mid-2026 VS-7375 data thesis or target window. |
||
|
2026-06-16 22:17:18
Event ID 749
Report 1585
|
VSTM
NO_CHANGE
|
PARTIALLY_REALIZED
ALERT
Parse: PARSED
|
YES_UP
Breakout:
DBR: {"expected_direction":"UP","directional_odds_up_down":"65_35","downside_risk":"HIGH","potential_high":"16.57","potential_low":"3.50","dbr_action":"REAFFIRM"}
|
VS-7375 program advanced, but mid-2026 updated data catalyst still pending Catalyst progress. First-patient dosing and Fast Track support VS-7375 momentum, but the thesis-defining updated data release has not yet occurred. |
||
|
2026-06-16 21:25:07
Event ID 748
Report 1569
|
CGEM
NO_CHANGE
|
PARTIALLY_REALIZED
Parse: PARSED
|
NONE
Breakout:
DBR: {"expected_direction":"PARTIAL_DELAY","directional_odds_up_down":"60_40","downside_risk":"HIGH","potential_high":"29.50","potential_low":"7.50","dbr_action":"REAFFIRM"}
|
CLN-978 initial autoimmune data released; main 2026 readouts still pending Catalyst progress. Initial CLN-978 data supports the thesis, but the new 8-K appears procedural and does not alter timing or target. |
||
|
2026-06-16 20:30:09
Event ID 747
Report 1591
|
CADL
REVISE
|
BROKEN
ALERT
Parse: PARSED
|
YES_DOWN
Breakout: 45
DBR: {"expected_direction":"PARTIAL_DELAY","directional_odds_up_down":"45_55","downside_risk":"HIGH","potential_high":"9.50","potential_low":"4.25","dbr_action":"REVISE"}
|
2026-06-16 to 2026-07-31 Target: $9.50 |
NSCLC Phase 3 initiation confirmation amid dilution overhang |
News indicated primary catalyst was delayed more than 30 days Catalyst progress. AUA data already landed, but financing-related 8-K suggests dilution pressure while the remaining NSCLC initiation catalyst likely extends beyond June. |
|
2026-06-16 20:09:45
Event ID 746
Report 1585
|
VSTM
NO_CHANGE
|
PARTIALLY_REALIZED
ALERT
Parse: PARSED
|
YES_UP
Breakout:
DBR: {"expected_direction":"UP","directional_odds_up_down":"65_35","downside_risk":"HIGH","potential_high":"16.57","potential_low":"3.50","dbr_action":"REAFFIRM"}
|
Updated VS-7375 data/progress cycle is underway, but thesis-defining mid-2026 data outcome is not fully disclosed here. Catalyst progress. Investor call and first-patient dosing support VS-7375 momentum within the existing window, but do not confirm the full data catalyst. |
||
|
2026-06-16 20:09:27
Event ID 745
Report 1585
|
VSTM
NO_CHANGE
|
ACTIVE
ALERT
Parse: PARSED
|
YES_UP
Breakout:
DBR: {"expected_direction":"UP","directional_odds_up_down":"65_35","downside_risk":"HIGH","potential_high":"16.57","potential_low":"3.50","dbr_action":"REAFFIRM"}
|
Original mid-2026 VS-7375 data catalyst still pending Catalyst progress. First-patient dosing in a registration-directed VS-7375 study supports pipeline momentum, but the thesis-defining mid-2026 data catalyst has not occurred. |
||
|
2026-06-16 19:51:38
Event ID 744
Report 1572
|
PRTA
NO_CHANGE
|
ACTIVE
Parse: PARSED
|
NONE
Breakout:
DBR: {"expected_direction":"UP","directional_odds_up_down":"65_35","downside_risk":"HIGH","potential_high":"14.00","potential_low":"6.50","dbr_action":"UNCHANGED"}
|
Primary PRX012 mid-2026 data catalyst remains pending within current window Catalyst progress. Conference participation does not deliver PRX012 data, so the mid-2026 readout thesis remains active and unchanged. |
||
|
2026-06-16 19:51:20
Event ID 743
Report 1572
|
PRTA
NO_CHANGE
|
ACTIVE
Parse: PARSED
|
NONE
Breakout:
DBR: {"expected_direction":"UP","directional_odds_up_down":"65_35","downside_risk":"HIGH","potential_high":"14.00","potential_low":"6.50","dbr_action":"UNCHANGED"}
|
Primary PRX012 mid-2026 readout still pending Catalyst progress. Partner Fast Track for PRX005 is supportive, but it does not replace or resolve the PRX012 mid-2026 data catalyst. |
||
|
2026-06-16 19:51:03
Event ID 742
Report 1572
|
PRTA
NO_CHANGE
|
ACTIVE
Parse: PARSED
|
NONE
Breakout:
DBR: {"expected_direction":"UP","directional_odds_up_down":"65_35","downside_risk":"HIGH","potential_high":"14.00","potential_low":"6.00","dbr_action":"UNCHANGED"}
|
Primary PRX012 mid-2026 data catalyst still pending Catalyst progress. Routine earnings-date announcement does not alter the pending PRX012 mid-2026 readout thesis or current target window. |
||
|
2026-06-16 19:50:29
Event ID 741
Report 1572
|
PRTA
NO_CHANGE
|
ACTIVE
Parse: PARSED
|
NONE
Breakout:
DBR: {"expected_direction":"UP","directional_odds_up_down":"65_35","downside_risk":"HIGH","potential_high":"14.00","potential_low":"6.00","dbr_action":"UNCHANGED"}
|
PRX012 mid-2026 readout remains pending within current window Catalyst progress. TDP-43 poster news is non-core and does not alter the pending PRX012 mid-2026 readout thesis. |
||
|
2026-06-16 19:50:09
Event ID 740
Report 1572
|
PRTA
NO_CHANGE
|
ACTIVE
Parse: PARSED
|
NONE
Breakout:
DBR: {"expected_direction":"UP","directional_odds_up_down":"65_35","downside_risk":"HIGH","potential_high":"14.00","potential_low":"6.00","dbr_action":"UNCHANGED"}
|
Primary PRX012 mid-2026 data catalyst still pending within window Catalyst progress. Earnings date announcement does not alter the pending mid-2026 PRX012 readout thesis or current target window. |
||
|
2026-06-16 19:46:39
Event ID 739
Report 1601
|
ONCY
NO_CHANGE
|
ACTIVE
Parse: PARSED
|
NONE
Breakout:
DBR: {"expected_direction":"UP","directional_odds_up_down":"60_40","downside_risk":"HIGH","potential_high":"2.50","potential_low":"0.55","dbr_action":"UNCHANGED"}
|
Main interim colorectal data catalyst remains pending Catalyst progress. Advisory-board formation supports strategy, but it does not change the year-end 2026 interim data catalyst or target window. |
||
|
2026-06-16 19:46:21
Event ID 738
Report 1601
|
ONCY
NO_CHANGE
|
ACTIVE
ALERT
Parse: PARSED
|
YES_UP
Breakout:
DBR: {"expected_direction":"UP","directional_odds_up_down":"65_35","downside_risk":"HIGH","potential_high":"2.50","potential_low":"0.55","dbr_action":"REAFFIRM"}
|
Original colorectal interim-data catalyst still pending within window Catalyst progress. FDA alignment in pancreatic cancer improves platform credibility, but the original colorectal interim-data catalyst for late 2026 has not yet occurred. |
||
|
2026-06-16 19:46:08
Event ID 737
Report 1601
|
ONCY
NO_CHANGE
|
ACTIVE
Parse: PARSED
|
NONE
Breakout:
DBR: {"expected_direction":"UP","directional_odds_up_down":"65_35","downside_risk":"HIGH","potential_high":"2.50","potential_low":"0.55","dbr_action":"UNCHANGED"}
|
Primary interim colorectal data catalyst still pending Catalyst progress. Shareholder-meeting update is non-core and does not alter the year-end 2026 interim data catalyst or target window. |
||
|
2026-06-16 19:45:45
Event ID 736
Report 1601
|
ONCY
NO_CHANGE
|
PARTIALLY_REALIZED
ALERT
Parse: PARSED
|
YES_UP
Breakout:
DBR: {"expected_direction":"UP","directional_odds_up_down":"65_35","downside_risk":"HIGH","potential_high":"2.50","potential_low":"0.55","dbr_action":"REAFFIRM"}
|
Supportive colorectal efficacy data emerged, but year-end 2026 interim Phase 2 catalyst remains pending. Catalyst progress. Positive colorectal data supports pelareorep, but the main interim randomized Phase 2 readout has not yet occurred. |
||
|
2026-06-16 19:41:58
Event ID 735
Report 1653
|
NGNE
NO_CHANGE
|
PARTIALLY_REALIZED
Parse: PARSED
|
NONE
Breakout:
DBR: {"expected_direction":"UP","directional_odds_up_down":"60_40","downside_risk":"HIGH","potential_high":"45.00","potential_low":"22.00","dbr_action":"REAFFIRM"}
|
Secondary catalyst completed; primary mid-2026 data catalyst still pending Catalyst progress. Inducement grants are non-catalytic, while Embolden dosing completion supports execution but the thesis-defining interim data has not yet arrived. |
||
|
2026-06-16 19:41:53
Event ID 734
Report 1653
|
NGNE
NO_CHANGE
|
PARTIALLY_REALIZED
Parse: PARSED
|
NONE
Breakout:
DBR: {"expected_direction":"UP","directional_odds_up_down":"60_40","downside_risk":"HIGH","potential_high":"45.00","potential_low":"22.00","dbr_action":"UNCHANGED"}
|
Embolden dosing completed, but mid-2026 interim Phase 1/2 data still pending Catalyst progress. Routine inducement grants do not affect the pending mid-2026 data catalyst or current breakout window. |
||
|
2026-06-16 19:41:41
Event ID 733
Report 1653
|
NGNE
NO_CHANGE
|
PARTIALLY_REALIZED
Parse: PARSED
|
NONE
Breakout:
DBR: {"expected_direction":"UP","directional_odds_up_down":"65_35","downside_risk":"HIGH","potential_high":"45.00","potential_low":"22.00","dbr_action":"REAFFIRM"}
|
Embolden dosing completion occurred, but mid-2026 interim Phase 1/2 data remain pending Catalyst progress. Embolden dosing completed, but the thesis-defining mid-2026 data catalyst remains pending and the inducement grant news is immaterial. |
||
|
2026-06-16 19:41:36
Event ID 732
Report 1653
|
NGNE
NO_CHANGE
|
PARTIALLY_REALIZED
Parse: PARSED
|
NONE
Breakout:
DBR: {"expected_direction":"UP","directional_odds_up_down":"65_35","downside_risk":"HIGH","potential_high":"45.00","potential_low":"22.00","dbr_action":"REAFFIRM"}
|
Secondary dosing catalyst hit; primary mid-2026 interim data catalyst still pending Catalyst hit. Embolden dosing completion supports execution, but the main price-setting mid-2026 Phase 1/2 data catalyst remains pending. |
||
|
2026-06-16 19:41:29
Event ID 731
Report 1653
|
NGNE
NO_CHANGE
|
PARTIALLY_REALIZED
ALERT
Parse: PARSED
|
YES_UP
Breakout:
DBR: {"expected_direction":"UP","directional_odds_up_down":"65_35","downside_risk":"HIGH","potential_high":"45.00","potential_low":"22.00","dbr_action":"REAFFIRM"}
|
Secondary catalyst completed; primary mid-2026 data catalyst still pending Catalyst progress. Embolden dosing completion strengthens execution and safety sentiment, but the main mid-2026 interim data catalyst has not yet occurred. |
||
|
2026-06-16 19:41:24
Event ID 730
Report 1653
|
NGNE
NO_CHANGE
|
PARTIALLY_REALIZED
Parse: PARSED
|
NONE
Breakout:
DBR: {"expected_direction":"UP","directional_odds_up_down":"65_35","downside_risk":"HIGH","potential_high":"45.00","potential_low":"22.00","dbr_action":"UNCHANGED"}
|
Embolden dosing catalyst occurred; mid-2026 interim data still pending Catalyst progress. Embolden dosing completion supports execution, but the breaking inducement-grant news does not alter the still-pending mid-2026 data catalyst. |
||
|
2026-06-16 19:41:17
Event ID 729
Report 1653
|
NGNE
NO_CHANGE
|
PARTIALLY_REALIZED
Parse: PARSED
|
NONE
Breakout:
DBR: {"expected_direction":"UP","directional_odds_up_down":"65_35","downside_risk":"HIGH","potential_high":"45.00","potential_low":"22.00","dbr_action":"REAFFIRM"}
|
Secondary catalyst hit; primary mid-2026 data catalyst still pending Catalyst hit. Embolden dosing completed, but the thesis-defining mid-2026 Phase 1/2 data update remains pending, so Catalyst progress supports but does not finish the thesis. |
||
|
2026-06-16 19:41:11
Event ID 728
Report 1653
|
NGNE
NO_CHANGE
|
PARTIALLY_REALIZED
Parse: PARSED
|
NONE
Breakout:
DBR: {"expected_direction":"UP","directional_odds_up_down":"65_35","downside_risk":"HIGH","potential_high":"45.00","potential_low":"20.00","dbr_action":"REAFFIRM"}
|
Secondary catalyst completed; primary mid-2026 data catalyst still pending Catalyst progress. Embolden dosing completed with supportive safety language, but the thesis-defining mid-2026 Phase 1/2 data update has not yet occurred. |
||
|
2026-06-16 19:41:01
Event ID 727
Report 1653
|
NGNE
REVISE
|
PARTIALLY_REALIZED
ALERT
Parse: PARSED
|
YES_UP
Breakout: 46
DBR: {"expected_direction":"UP","directional_odds_up_down":"62_38","downside_risk":"HIGH","potential_high":"45.00","potential_low":"22.00","dbr_action":"REVISE"}
|
2026-06-10 to 2026-07-31 Target: $45.00 |
Mid-2026 interim Phase 1/2 NGN-401 safety and efficacy data remains the primary catalyst after Embolden dosing completion was achieved |
Secondary execution catalyst achieved; primary mid-2026 data catalyst still pending Catalyst hit. Embolden dosing completion de-risks execution, and Catalyst progress. clean safety language modestly strengthens odds ahead of the still-pending mid-2026 data update. |
|
2026-06-16 19:27:48
Event ID 726
Report 1632
|
HIND
NO_CHANGE
|
PARTIALLY_REALIZED
Parse: PARSED
|
NONE
Breakout:
DBR: {"expected_direction":"PARTIAL_DELAY","directional_odds_up_down":"55_45","downside_risk":"HIGH","potential_high":"4.50","potential_low":"1.60","dbr_action":"REAFFIRM"}
|
FDA submissions for ODD and pivotal-development readiness were confirmed, but no orphan decision or Phase 3 initiation yet Catalyst progress. Non-VT-1953 licensing is not the thesis driver, while FDA submission progress supports but does not complete the June VT-1953 catalyst. |
||
|
2026-06-16 19:09:28
Event ID 725
Report 1668
|
ATYR
NO_CHANGE
|
ACTIVE
Parse: PARSED
|
NONE
Breakout:
DBR: {"expected_direction":"PARTIAL_DELAY","directional_odds_up_down":"55_45","downside_risk":"HIGH","potential_high":"0.95","potential_low":"0.40","dbr_action":"UNCHANGED"}
|
Primary June 2026 IND submission catalyst still pending confirmation Catalyst progress. The lawsuit headline is stale, non-operational, and does not alter the June 2026 IND catalyst window or core restart thesis. |
||
|
2026-06-16 18:25:56
Event ID 724
Report 1663
|
ACET
NO_CHANGE
|
ACTIVE
Parse: PARSED
|
NONE
Breakout:
DBR: {"expected_direction":"PARTIAL_DELAY","directional_odds_up_down":"55_45","downside_risk":"HIGH","potential_high":"15.50","potential_low":"6.00","dbr_action":"REAFFIRM"}
|
Main LN/SLE data and FDA-path catalyst still pending Catalyst progress. First SSc dosing supports platform expansion, but it does not resolve the LN/SLE mid-2026 data and FDA-path catalyst driving the prediction. |
||
|
2026-06-16 18:25:35
Event ID 723
Report 1663
|
ACET
NO_CHANGE
|
ACTIVE
Parse: PARSED
|
NONE
Breakout:
DBR: {"expected_direction":"UP","directional_odds_up_down":"70_30","downside_risk":"HIGH","potential_high":"15.50","potential_low":"5.50","dbr_action":"UNCHANGED"}
|
Primary mid-2026 clinical and FDA-path catalysts remain pending Catalyst progress. A conference fireside chat adds visibility but does not change the pending mid-2026 prula-cel data and FDA-path thesis. |
||
|
2026-06-16 18:25:16
Event ID 722
Report 1663
|
ACET
NO_CHANGE
|
ACTIVE
Parse: PARSED
|
NONE
Breakout:
DBR: {"expected_direction":"PARTIAL_DELAY","directional_odds_up_down":"55_45","downside_risk":"HIGH","potential_high":"15.50","potential_low":"5.50","dbr_action":"REAFFIRM"}
|
Primary mid-2026 LN/SLE data and FDA path catalyst still pending Catalyst progress. Q2 2025 update supports ongoing execution but does not deliver the thesis-defining mid-2026 autoimmune data or FDA pivotal-path outcome. |
||
|
2026-06-16 18:24:24
Event ID 721
Report 1663
|
ACET
NO_CHANGE
|
ACTIVE
Parse: PARSED
|
NONE
Breakout:
DBR: {"expected_direction":"UP","directional_odds_up_down":"70_30","downside_risk":"HIGH","potential_high":"15.50","potential_low":"6.50","dbr_action":"UNCHANGED"}
|
Historical positive preliminary data already resolved; main mid-2026 data/FDA catalyst still pending Catalyst progress. The breaking item is old preliminary data and does not alter the pending 2026 data/FDA catalyst window. |
||
|
2026-06-16 18:24:07
Event ID 720
Report 1663
|
ACET
NO_CHANGE
|
ACTIVE
Parse: PARSED
|
NONE
Breakout:
DBR: {"expected_direction":"UP","directional_odds_up_down":"60_40","downside_risk":"HIGH","potential_high":"15.50","potential_low":"6.00","dbr_action":"UNCHANGED"}
|
Primary mid-2026 clinical and FDA-path catalysts still pending Catalyst progress. The offering is historical, already reflected in context, and does not alter the pending mid-2026 data or FDA catalyst window. |
||
|
2026-06-16 18:23:40
Event ID 719
Report 1663
|
ACET
NO_CHANGE
|
ACTIVE
Parse: PARSED
|
NONE
Breakout:
DBR: {"expected_direction":"UP","directional_odds_up_down":"60_40","downside_risk":"HIGH","potential_high":"15.50","potential_low":"5.50","dbr_action":"REAFFIRM"}
|
Primary mid-2026 data and FDA-path catalyst still pending Catalyst progress. The Guggenheim fireside chat is only a visibility event and does not change the pending mid-2026 clinical/FDA catalyst. |
||
|
2026-06-16 18:23:15
Event ID 718
Report 1663
|
ACET
NO_CHANGE
|
ACTIVE
Parse: PARSED
|
NONE
Breakout:
DBR: {"expected_direction":"UP","directional_odds_up_down":"60_40","downside_risk":"HIGH","potential_high":"15.50","potential_low":"5.50","dbr_action":"REAFFIRM"}
|
Primary mid-2026 prula-cel data and FDA path catalyst still pending Catalyst progress. Quarterly update reiterates timing and runway, but no thesis-defining prula-cel data or pivotal-path outcome was delivered. |
||
|
2026-06-16 18:22:49
Event ID 717
Report 1663
|
ACET
NO_CHANGE
|
ACTIVE
Parse: PARSED
|
NONE
Breakout:
DBR: {"expected_direction":"UP","directional_odds_up_down":"60_40","downside_risk":"HIGH","potential_high":"15.50","potential_low":"5.50","dbr_action":"UNCHANGED"}
|
Primary mid-2026 clinical and FDA-path catalysts still pending Inducement grant is non-catalytic compensation news; Catalyst progress. it does not alter timing, probability, or value of the pending prula-cel data thesis. |
||
|
2026-06-16 16:10:10
Event ID 716
Report 1658
|
IRD
REVISE
|
BROKEN
Parse: PARSED
|
NONE
Breakout: 37
DBR: {"expected_direction":"PARTIAL_DELAY","directional_odds_up_down":"55_45","downside_risk":"HIGH","potential_high":"6.20","potential_low":"3.20","dbr_action":"REVISE"}
|
2026-06-16 to 2026-09-30 Target: $6.20 |
Shift from June forum recap to September 2026 OPGx-BEST1 Cohort 1 topline data and any intervening LCA5 pathway clarification. |
News indicated primary catalyst was delayed more than 30 days Catalyst progress. The 8-K appears to document the June event without clear new results, shifting the next meaningful catalyst to September BEST1 topline data. |
|
2026-06-16 13:10:13
Event ID 715
Report 1601
|
ONCY
NO_CHANGE
|
ACTIVE
Parse: PARSED
|
NONE
Breakout:
DBR: {"expected_direction":"UP","directional_odds_up_down":"60_40","downside_risk":"HIGH","potential_high":"2.50","potential_low":"0.55","dbr_action":"REAFFIRM"}
|
Interim colorectal data catalyst still pending for year-end 2026 Catalyst progress. Patent and 8-K language support strategy, but no interim colorectal data or delayed timing changes the year-end thesis. |
||
|
2026-06-16 13:03:47
Event ID 714
Report 1601
|
ONCY
NO_CHANGE
|
ACTIVE
ALERT
Parse: PARSED
|
YES_UP
Breakout:
DBR: {"expected_direction":"UP","directional_odds_up_down":"60_40","downside_risk":"HIGH","potential_high":"2.50","potential_low":"0.55","dbr_action":"REAFFIRM"}
|
Primary interim colorectal data catalyst still pending Catalyst progress. New patent modestly supports commercialization credibility, but the year-end 2026 interim colorectal data remains the thesis-defining catalyst. |
||
|
2026-06-16 13:02:17
Event ID 713
Report 1630
|
CELZ
NO_CHANGE
|
ACTIVE
Parse: PARSED
|
NONE
Breakout:
DBR: {"expected_direction":"PARTIAL_DELAY","directional_odds_up_down":"55_45","downside_risk":"HIGH","potential_high":"4.25","potential_low":"1.60","dbr_action":"UNCHANGED"}
|
ADAPT final data catalyst still pending Catalyst progress. Burn-pit registry expansion is non-core to the ADAPT thesis and does not change the June 30 ADAPT catalyst window. |
||
|
2026-06-16 12:34:39
Event ID 712
Report 1605
|
ENTX
NO_CHANGE
|
PARTIALLY_REALIZED
ALERT
Parse: PARSED
|
YES_UP
Breakout:
DBR: {"expected_direction":"UP","directional_odds_up_down":"65_35","downside_risk":"HIGH","potential_high":"3.50","potential_low":"0.90","dbr_action":"REAFFIRM"}
|
Supportive EB613 clinical progress disclosed, but FDA feedback catalyst remains pending Catalyst progress. New EB613 and pipeline data support platform value, but the main EB613 FDA feedback catalyst has not yet occurred. |
||
|
2026-06-15 20:45:09
Event ID 711
Report 1577
|
CHRS
NO_CHANGE
|
ACTIVE
Parse: PARSED
|
NONE
Breakout:
DBR: {"expected_direction":"PARTIAL_DELAY","directional_odds_up_down":"55_45","downside_risk":"HIGH","potential_high":"2.50","potential_low":"1.10","dbr_action":"REAFFIRM"}
|
Primary first-half 2026 clinical data catalyst still pending Catalyst progress. The 8-K appears accountant/regulatory related and does not confirm or delay the expected CHS-114 or Casdozokitug data readouts. |
||
|
2026-06-15 12:46:58
Event ID 710
Report 1605
|
ENTX
MODIFIED
|
PARTIALLY_REALIZED
ALERT
Parse: PARSED
|
YES_UP
Breakout: 65%
DBR: {"expected_direction":"UP","directional_odds_up_down":"65_35","downside_risk":"HIGH","potential_high":"3.25","potential_low":"0.90","dbr_action":"REVISE"}
|
2026-06-15 to 2026-12-31 Target: $3.25 |
FDA feedback on EB613 Phase 3 plan plus single-tablet advancement support |
Supportive EB613 clinical progress disclosed, but FDA feedback catalyst remains pending Catalyst progress. New EB613 single-tablet data strengthens program credibility, but Catalyst hit. has not occurred because FDA feedback is still pending. |
|
2026-06-15 12:02:00
Event ID 709
Report 1648
|
NMRA
MODIFIED
|
BROKEN
ALERT
Parse: PARSED
|
YES_DOWN
Breakout: 2%
DBR: {"expected_direction":"DOWN","directional_odds_up_down":"10_90","downside_risk":"HIGH","potential_high":"0.90","potential_low":"0.50","dbr_action":"REVISE"}
|
2026-06-15 to 2026-06-15 Target: $0.90 |
KOASTAL-2 and KOASTAL-3 Phase 3 data missed and navacaprant development was discontinued |
Phase 3 KOASTAL-2 and KOASTAL-3 failed and navacaprant was discontinued Catalyst hit. Phase 3 KOASTAL data failed, navacaprant was discontinued, and Catalyst progress shifted to secondary pipeline programs. |
|
2026-06-15 11:10:23
Event ID 708
Report 1659
|
LXEO
REVISE
|
PARTIALLY_REALIZED
ALERT
Parse: PARSED
|
YES_UP
Breakout: 46
DBR: {"expected_direction":"UP","directional_odds_up_down":"65_35","downside_risk":"MEDIUM","potential_high":"7.25","potential_low":"3.75","dbr_action":"REVISE"}
|
2026-06-15 to 2026-06-30 Target: $7.25 |
Finalized SUNRISE-FA 2 protocol with first-patient enrollment expected by end of June |
Protocol and SAP finalized, but trial initiation and first-patient enrollment are still pending Catalyst progress: protocol finalization de-risks FDA path, but Catalyst hit. has not fully occurred because enrollment initiation remains pending. |
|
2026-06-15 11:02:30
Event ID 707
Report 1659
|
LXEO
MODIFIED
|
PARTIALLY_REALIZED
ALERT
Parse: PARSED
|
YES_UP
Breakout: 52%
DBR: {"expected_direction":"UP","directional_odds_up_down":"65_35","downside_risk":"MEDIUM","potential_high":"7.25","potential_low":"3.60","dbr_action":"REVISE"}
|
2026-06-15 to 2026-06-30 Target: $7.25 |
Finalized SUNRISE-FA 2 protocol with FDA alignment and expected first-patient enrollment by end of June |
FDA-aligned protocol finalization occurred, while pivotal trial initiation and first-patient enrollment remain pending Catalyst progress. FDA-aligned protocol finalization de-risks LX2006 and supports upside, but trial initiation and first-patient enrollment are not yet fully completed. |
|
2026-06-15 11:02:18
Event ID 706
Report 1624
|
ELTX
MODIFIED
|
BROKEN
ALERT
Parse: PARSED
|
YES_DOWN
Breakout: 24%
DBR: {"expected_direction":"DOWN","directional_odds_up_down":"30_70","downside_risk":"HIGH","potential_high":"16.00","potential_low":"7.00","dbr_action":"REVISE"}
|
2026-06-15 to 2026-09-30 Target: $16.00 |
Post-readout regulatory feedback, financing or partnership progress, and Phase 3 initiation planning after mixed Phase 2 results |
News indicated primary catalyst was delayed more than 30 days Catalyst hit. Mixed Phase 2 data missed the primary endpoint, but subgroup signals and Phase 3 refinement preserve some residual upside. |
|
2026-06-12 22:15:07
Event ID 705
Report 1572
|
PRTA
NO_CHANGE
|
ACTIVE
ALERT
Parse: PARSED
|
YES_UP
Breakout:
DBR: {"expected_direction":"UP","directional_odds_up_down":"60_40","downside_risk":"HIGH","potential_high":"14.00","potential_low":"6.50","dbr_action":"REAFFIRM"}
|
Primary PRX012 mid-2026 data catalyst still pending Catalyst progress. Insider buying supports sentiment, but the PRX012 data catalyst has not occurred and the August 2026 window remains intact. |
||
|
2026-06-12 21:30:47
Event ID 704
Report 1635
|
TRAW
MODIFIED
|
BROKEN
ALERT
Parse: PARSED
|
YES_DOWN
Breakout: 18%
DBR: {"expected_direction":"DOWN","directional_odds_up_down":"20_80","downside_risk":"HIGH","potential_high":"1.80","potential_low":"0.75","dbr_action":"REVISE"}
|
2026-06-12 to 2026-08-15 Target: $1.80 |
Strategic reset after MHRA setback, with any updated influenza regulatory path or final ratutrelvir Phase 2a analysis now the next meaningful catalysts |
News indicated primary catalyst was delayed more than 30 days Catalyst hit. Negative MHRA review deferred the planned tivoxavir challenge study, breaking the near-term approval thesis and pushing meaningful influenza catalysts beyond the window. |
|
2026-06-12 21:30:07
Event ID 703
Report 1635
|
TRAW
NO_CHANGE
|
ACTIVE
Parse: PARSED
|
NONE
Breakout:
DBR: {"expected_direction":"PARTIAL_DELAY","directional_odds_up_down":"55_45","downside_risk":"HIGH","potential_high":"3.20","potential_low":"0.95","dbr_action":"REAFFIRM"}
|
Primary MHRA approval catalyst still pending Catalyst progress: the 8-K signal suggests clinical-trial discussion, but no disclosed MHRA approval or final ratutrelvir analysis means the thesis remains pending. |
||
|
2026-06-12 20:35:14
Event ID 702
Report 1654
|
ABEO
NO_CHANGE
|
ACTIVE
Parse: PARSED
|
NONE
Breakout:
DBR: {"expected_direction":"UNCERTAIN","directional_odds_up_down":"55_45","downside_risk":"MEDIUM","potential_high":"7.40","potential_low":"4.60","dbr_action":"UNCHANGED"}
|
Commercial launch thesis remains pending; 8-K appears governance/meeting related, not catalyst-defining. Catalyst progress. The 8-K does not show a new ZEVASKYN launch update or thesis-defining commercial outcome. |
||
|
2026-06-12 11:35:08
Event ID 701
Report 1654
|
ABEO
NO_CHANGE
|
ACTIVE
Parse: PARSED
|
NONE
Breakout:
DBR: {"expected_direction":"UNCERTAIN","directional_odds_up_down":"50_50","downside_risk":"MEDIUM","potential_high":"7.40","potential_low":"4.70","dbr_action":"UNCHANGED"}
|
Commercial launch catalyst still pending; filing evidence is non-specific Catalyst progress. The 8-K signal lacks confirmed commercial or regulatory substance, so the ZEVASKYN launch-traction thesis remains unchanged. |
||
|
2026-06-12 08:08:51
Event ID 700
Report 1656
|
AUTL
NO_CHANGE
|
ACTIVE
Parse: PARSED
|
NONE
Breakout:
DBR: {"expected_direction":"UP","directional_odds_up_down":"60_40","downside_risk":"HIGH","potential_high":"2.60","potential_low":"1.20","dbr_action":"UNCHANGED"}
|
Primary Q2 commercial update catalyst still pending in August 2026 Catalyst progress. Award recognition is positive but does not change the August commercial execution catalyst or target odds materially. |
||
|
2026-06-11 20:10:29
Event ID 699
Report 1588
|
ALXO
REVISE
|
BROKEN
Parse: PARSED
|
NONE
Breakout: 50
DBR: {"expected_direction":"PARTIAL_DELAY","directional_odds_up_down":"45_55","downside_risk":"HIGH","potential_high":"3.75","potential_low":"1.10","dbr_action":"REVISE"}
|
2026-10-01 to 2027-07-31 Target: $3.75 |
ASPEN-09 topline breast cancer data now guided for mid-2027 |
News indicated primary catalyst was delayed more than 30 days Catalyst progress. Company shifted ASPEN-09 topline data to mid-2027, pushing the main thesis beyond the original 2026 window. |
|
2026-06-11 12:56:07
Event ID 698
Report 1625
|
IGC
MODIFIED
|
PARTIALLY_REALIZED
ALERT
Parse: PARSED
|
YES_UP
Breakout: 42%
DBR: {"expected_direction":"PARTIAL_DELAY","directional_odds_up_down":"55_45","downside_risk":"HIGH","potential_high":"0.45","potential_low":"0.24","dbr_action":"REVISE"}
|
2026-06-11 to 2026-08-01 Target: $0.45 |
Database activities and subsequent topline Phase 2 CALMA analysis after enrollment target reached |
Enrollment target reached, but topline analysis remains pending Catalyst hit. Enrollment completion shifts focus to later topline analysis, extending timing while funding risk and over-enrollment temper near-term upside. |
|
2026-06-10 20:20:19
Event ID 697
Report 1654
|
ABEO
NO_CHANGE
|
ACTIVE
Parse: PARSED
|
NONE
Breakout:
DBR: {"expected_direction":"UNCERTAIN","directional_odds_up_down":"50_50","downside_risk":"MEDIUM","potential_high":"7.40","potential_low":"4.70","dbr_action":"UNCHANGED"}
|
Commercial launch catalyst still pending Catalyst progress. The 8-K signal lacks clear new commercial or regulatory substance, so it does not alter the near-term ZEVASKYN launch thesis. |
||
|
2026-06-10 20:15:26
Event ID 696
Report 1560
|
AEMD
MODIFIED
|
BROKEN
Parse: PARSED
|
NONE
Breakout: 30%
DBR: {"expected_direction":"PARTIAL_DELAY","directional_odds_up_down":"40_60","downside_risk":"HIGH","potential_high":"4.00","potential_low":"0.50","dbr_action":"REVISE"}
|
2025-11-01 to 2026-09-30 Target: $4.00 |
Australian oncology trial completion and preliminary cohort analysis |
News indicated primary catalyst was delayed more than 30 days Catalyst progress. Cohort 3 started, but data remain pending and timing now appears beyond June 30, reducing odds of the original target. |
|
2026-06-10 20:10:41
Event ID 695
Report 1583
|
SNES
NO_CHANGE
|
PARTIALLY_REALIZED
Parse: PARSED
|
NONE
Breakout:
DBR: {"expected_direction":"PARTIAL_DELAY","directional_odds_up_down":"60_40","downside_risk":"HIGH","potential_high":"3.50","potential_low":"1.30","dbr_action":"REAFFIRM"}
|
Bermuda distribution supports international expansion; primary approvals catalyst still unresolved Catalyst progress. Bermuda expansion and insider buying help, but the 8-K appears governance-related and does not confirm a new approval catalyst. |
||
|
2026-06-10 20:05:10
Event ID 694
Report 1646
|
PYPD
REVISE
|
BROKEN
ALERT
Parse: PARSED
|
YES_DOWN
Breakout: 46
DBR: {"expected_direction":"PARTIAL_DELAY","directional_odds_up_down":"45_55","downside_risk":"HIGH","potential_high":"6.25","potential_low":"3.40","dbr_action":"REVISE"}
|
2026-06-10 to 2026-08-15 Target: $6.25 |
FDA filing acceptance and review-path clarity after completed NDA, with financing overhang now a counterweight |
News indicated primary catalyst was delayed more than 30 days Catalyst hit. Completed NDA shifts focus to FDA acceptance, while financing signals dilution risk and likely weakens near-term upside odds. |
|
2026-06-10 11:40:09
Event ID 693
Report 1569
|
CGEM
NO_CHANGE
|
PARTIALLY_REALIZED
ALERT
Parse: PARSED
|
YES_UP
Breakout:
DBR: {"expected_direction":"UP","directional_odds_up_down":"65_35","downside_risk":"HIGH","potential_high":"29.50","potential_low":"7.50","dbr_action":"REAFFIRM"}
|
Initial CLN-978 autoimmune data released; key later-2026 readouts still pending Catalyst hit. Initial autoimmune data support CLN-978, while additional RA and SLE updates later in 2026 keep the broader thesis only partially realized. |
||
|
2026-06-10 11:31:48
Event ID 692
Report 1569
|
CGEM
MODIFIED
|
PARTIALLY_REALIZED
ALERT
Parse: PARSED
|
YES_UP
Breakout: 80%
DBR: {"expected_direction":"UP","directional_odds_up_down":"75_25","downside_risk":"HIGH","potential_high":"29.50","potential_low":"8.50","dbr_action":"REVISE"}
|
2026-06-10 to 2026-12-31 Target: $29.50 |
Initial CLN-978 autoimmune data released; further CLN-978, velinotamig, and zipalertinib readouts remain in 2026 |
Initial CLN-978 autoimmune data delivered, but key additional 2026 readouts remain pending Catalyst hit. Positive autoimmune data and outlined near-term follow-up readouts strengthen the 2026 thesis without moving the main catalyst window beyond year-end. |
|
2026-06-09 20:30:14
Event ID 691
Report 1583
|
SNES
NO_CHANGE
|
PARTIALLY_REALIZED
ALERT
Parse: PARSED
|
YES_UP
Breakout:
DBR: {"expected_direction":"UP","directional_odds_up_down":"65_35","downside_risk":"MEDIUM","potential_high":"3.50","potential_low":"1.40","dbr_action":"REAFFIRM"}
|
International expansion progressed; main approval catalyst still pending Catalyst progress. Insider buying and Bermuda distribution support sentiment, but the core additional-approvals catalyst within the July window is not yet fully hit. |
||
|
2026-06-09 12:48:57
Event ID 690
Report 1625
|
IGC
NO_CHANGE
|
ACTIVE
Parse: PARSED
|
NONE
Breakout:
DBR: {"expected_direction":"UP","directional_odds_up_down":"60_40","downside_risk":"HIGH","potential_high":"0.52","potential_low":"0.24","dbr_action":"REAFFIRM"}
|
Enrollment completion catalyst still pending Catalyst progress. Analyst target publicity supports sentiment, but no CALMA enrollment completion or topline data has occurred within the current window. |
||
|
2026-06-09 12:07:37
Event ID 689
Report 1590
|
ACOG
MODIFIED
|
REALIZED
ALERT
Parse: PARSED
|
YES_UP
Breakout: 55%
DBR: {"expected_direction":"UP","directional_odds_up_down":"65_35","downside_risk":"MEDIUM","potential_high":"9.50","potential_low":"4.75","dbr_action":"REVISE"}
|
2026-06-09 to 2026-08-31 Target: $9.50 |
BEACON topline results released; focus shifts to commercial uptake and payer adoption |
BEACON topline results were released with positive provider-reported findings Catalyst hit. Positive BEACON topline data supports ZUNVEYL adoption, though observational design tempers conviction versus controlled evidence. |
|
2026-06-09 11:35:17
Event ID 688
Report 1656
|
AUTL
REVISE
|
ACTIVE
ALERT
Parse: PARSED
|
YES_DOWN
Breakout: 31
DBR: {"expected_direction":"DOWN","directional_odds_up_down":"35_65","downside_risk":"HIGH","potential_high":"2.40","potential_low":"1.20","dbr_action":"REVISE"}
|
2026-07-30 to 2026-08-18 Target: $2.40 |
Q2 2026 commercial update remains primary catalyst, but interim financing overhang may cap rerating |
Primary Q2 commercial catalyst still pending; financing signal adds overhang but does not resolve thesis Catalyst progress. Financing-related SEC signals imply dilution/runway overhang before the August commercial update, weakening odds of reaching the prior target. |
|
2026-06-09 10:15:10
Event ID 687
Report 1598
|
ATHE
REVISE
|
BROKEN
ALERT
Parse: PARSED
|
YES_UP
Breakout: 68
DBR: {"expected_direction":"UP","directional_odds_up_down":"72_28","downside_risk":"MEDIUM","potential_high":"7.00","potential_low":"2.80","dbr_action":"REVISE"}
|
2026-06-09 to 2026-08-31 Target: $7.00 |
FDA-aligned Phase 3 program confirmation and potential Phase 3 initiation |
News indicated primary catalyst was delayed more than 30 days Catalyst hit. FDA alignment de-risks ATH434, and Catalyst progress. Phase 3 initiation now becomes the next meaningful upside driver beyond July. |
|
2026-06-08 22:25:09
Event ID 686
Report 1583
|
SNES
NO_CHANGE
|
PARTIALLY_REALIZED
ALERT
Parse: PARSED
|
YES_UP
Breakout:
DBR: {"expected_direction":"UP","directional_odds_up_down":"65_35","downside_risk":"HIGH","potential_high":"3.50","potential_low":"1.30","dbr_action":"REAFFIRM"}
|
Distribution expansion occurred; primary approvals thesis still ongoing Catalyst progress. Insider buying and Bermuda distribution support commercial momentum, but the original international-approvals catalyst remains only partially realized within the window. |
||
|
2026-06-08 20:15:43
Event ID 685
Report 1661
|
ACHV
REVISE
|
ACTIVE
ALERT
Parse: PARSED
|
YES_DOWN
Breakout: 37
DBR: {"expected_direction":"PARTIAL_DELAY","directional_odds_up_down":"55_45","downside_risk":"HIGH","potential_high":"8.50","potential_low":"3.20","dbr_action":"REVISE"}
|
2026-06-10 to 2026-06-24 Target: $8.50 |
FDA decision on cytisinicline NDA remains primary catalyst; proxy-linked financing disclosure adds dilution overhang. |
Primary FDA decision catalyst still pending Catalyst progress: FDA thesis is still pending, but proxy financing disclosure reinforces dilution overhang and modestly weakens near-term upside odds. |
|
2026-06-08 20:10:45
Event ID 684
Report 1625
|
IGC
NO_CHANGE
|
ACTIVE
Parse: PARSED
|
NONE
Breakout:
DBR: {"expected_direction":"UNCERTAIN","directional_odds_up_down":"50_50","downside_risk":"HIGH","potential_high":"0.52","potential_low":"0.24","dbr_action":"UNCHANGED"}
|
Enrollment-completion catalyst still pending Catalyst progress. The 8-K signal lacks confirmed CALMA enrollment completion or delay, so the original mid-2026 catalyst window remains intact. |